Drugs / RABUSERTIB
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01358968 | Jun 2011 → Apr 2012 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01341457 | May 2011 → Jun 2013 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01296568 | Feb → Dec 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00415636 | Jan 2007 → Mar 2010 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01139775 | Feb 2011 → May 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT00839332 | Feb 2009 → Feb 2013 | malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00988858 | Nov 2009 → Jul 2012 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RABUSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039517 ↗ |
| Known as | IC83 | “Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer” NCT00415636 ↗ |
| Known as | LY2603618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358968 ↗ |
| Action | Inhibit | “checkpoint kinase 1 inihibitor (CHK1), LY2603618” PMID 28202004 ↗ Feb 2017 |
| Modality | Small molecule | — CHEMBL3039517 ↗ |
| Route | Intravenous | “LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m\^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks” NCT00839332 ↗ |
| Target | CHEK1 | “LY2603618 is an inhibitor of checkpoint kinase 1 (CHK1), an important regulator of the DNA damage checkpoints.” PMID 24942404 ↗ Jun 2014 |